Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.66 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | COMT | P21964 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18499549 | 0.84 | BTK (0.65) | BTKEGFR | |
| SCHEMBL16337884 | 0.80 | BTK (1.00) | BTK | |
| SCHEMBL21008559 | 0.72 | BTK (0.65) | BTK | |
| SCHEMBL18499586 | 0.69 | BTK (0.69) | BTKEGFRLMNA | |
| SCHEMBL16338291 | 0.68 | BTK (1.00) | BTK | |
| SCHEMBL16168729 | 0.68 | POLB (0.63) | NOTUMCOMTHPGDSNOS3NOS1 | |
| SCHEMBL16336006 | 0.63 | BTK (1.00) | BTK | |
| SCHEMBL29709483 | 0.63 | BTK (1.00) | BTK | |
| SCHEMBL16338243 | 0.61 | BTK (0.71) | BTK | |
| SCHEMBL16336907 | 0.61 | BTK (1.00) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | BTK 1/4885NOTUM 1324/4885EGFR 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.